Alzheimer's disease (AD) in patients receiving stable donepezil treatment compared with not providing memantine. METHODS: Data from a U.S. multicenter randomised clinical trial that compared memantine versus placebo in moderate to severe AD patients on stable doses of donepezil was used to evaluate the cost effectiveness of providing memantine to donepezil. Using methodology developed by Kurz et al., patients were classified at each visit as dependent or non-dependent according to their ADCS-ADL19 scores. Mean weekly costs were estimated from the National Health Service and Personal Social Services perspectives for patients with MMSE £14 that participated in a UK epidemiological study-the LASER-AD study. QALYs per dependency were estimated from a Danish Study. Per week mean acquisition cost and effectiveness of treatment were £975; 0.6511 and £288; 0.3207 for dependent and non-dependent patients. Total drug costs for the 24-week period were £492 for donepezil and £937 for memantine plus donepezil. Costs, QALYs and time of non-dependence were associated with each dependency level and added to obtain total outcomes over the 24-week study period. RESULTS: Over the evaluation period, memantine added to patients stabilised on donepezil was associated with an additional 0.0112 QALYs, an additional 1.77 weeks of independence and a £771 cost reduction compared with donepezil alone. The cost reduction is not statistically significant but suggests that clinical advantages offset some of the cost of adding memantine. CONCLUSION: This analysis suggests that memantine treatment provided to patients receiving stable donepezil treatment is cost-effective compared with not adding memantine. As costs and QALYs were assessed retrospectively, further prospective studies are required to support this finding. 4 GlaxoSmithKline Ireland, Dublin, Ireland OBJECTIVE: To estimate the overall burden of pediatric epilepsy on the family and Irish health care system and to establish whether there is a relationship between epilepsy profile and this burden. METHOD: The sample was drawn from a population of children with epilepsy attending a tertiary pediatric neurology clinic in Dublin. Data was collected prospectively on health care resource use and time lost from school and work. Diary cards were completed at three monthly intervals. RESULTS: Complete data was available on 127 children aged 15 months to 16.7 years (median 8.8), 54% were male and 52% lived in a rural setting. A total of 61% had cryptogenic or symptomatic epilepsy, 63% had partial seizures and 53% had frequent seizures (>10 seizures/month). The annual cost of epilepsy was significantly higher for those with cryptogenic/symptomatic epilepsy (€9248) and frequent seizures (€9145) relative to idiopathic epilepsy (€2600) and no/infrequent seizures (€3951) (P < 0.0001). Children with frequent seizures had a higher risk of being hospitalised (P = 0.03) and lost more days at school (P < 0.0005). 50% of families contacted the pediatric liaison nurse, and 12% made more than 5 contacts. Five percent of children attended their GP while 37% of families had independently sought complementary medicine. CONCLUSIONS: The economic and social burden of pediatric epilepsy is substantial and relates to the epilepsy syndrome and frequency of seizures. In this prospective study a large dependence on epilepsy liaison nurse support was found, an area that requires extra resources. A large number of families also sought advice from non medical sources. The aim of this prospective study was to determine the relationship between seizure type, seizure frequency and epilepsy syndrome on the quality of life of both the child and family over a one year period. METHOD: The sample was drawn from a population of children with epilepsy attending a tertiary Paediatric Neurology service in Dublin. Data was collected on seizure type and frequency, epilepsy syndrome, physi-
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PNL3 RETROSPECTIVE COMPARATIVE ANALYSIS OF ANTIDEMENTIA MEDICATION PERSISTENCE PATTERNS AT 3 YEARS IN SPANISH ALZHEIMER DISEASE PATIENTS TREATED WITH DONEPEZIL, RIVASTIGMINE, GALANTAMINE AND MEMANTINE
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PNL5 A PROSPECTIVE STUDY ON THE IMPACT OF A CHILD'S EPILEPSY ON THEIR QUALITY OF LIFE AND THEIR FAMILY
PNL6 THE EPIDEMIOLOGY AND MANAGEMENT OF MIGRAINE IN THE UK
PNL7 IS THE TREATMENT OF ACUTE MIGRAINE WITH TRIPTANS EFFICIENT FROM A SOCIETAL PERSPECTIVE?
Gracia-Naya M 1 , Díaz S 2 , Latorre A 1 , Rejas J 3 1 Miguel Servet Hospital, Zaragoza, Zaragoza, Spain; 2 Euriclin Institute, Madrid, Madrid, Spain; 3 Pfizer Spain, Alcobendas/Madrid, Spain OBJECTIVE: To carry out a one-year cost benefit analysis from the Year-2005 societal perspective of the acute migraine attacks treatment in Spain. METHODS: A cost-benefits analysis was performed. Model data were obtained from the Spanish cohort of a multinational survey assessing impact of migraine on disability, absenteeism and health care resource utilization. Benefits (days of disability and health resources use avoided) were computed indirectly by imputation of the effectiveness (anti-migraine complete response) obtained from a published efficacy metaanalysis of available triptans in Spain. Human capital method was used for imputation indirect costs and benefits. Results are expressed as net benefits. Sensibility analysis was performed. RESULTS: The number of annual migraine attacks was 57.7 (95% confidence interval: 44.5-77.2), the paid and unpaid annual lost-workday-equivalents (LWDE) were 34.9 (22.8-68.3) and 37.5 (27.0-54.1), respectively. The annual cost of untreated migraine was €4077.70 (3145.1-5451.0). Migraine treatment reduced the number of LWDEs per year between 7.5 (5.2-12.7) with zolmitriptan-2.5, to 14.7 (10.1-24.8) with eletriptan-40 and rizatriptan-10. Compared with no-treatment, the average annual net benefits obtained were: eletriptan-40; €269.50 (207.9-360.3), rizatriptan-10; €226.20 (174.5-302.4), sumatriptan-50; €185.80 (143.3-248.4); naratriptan-2.5; €126.40 (97.5-169.0), and almotriptan-12.5; €8.40 (6.4-11.2). Zolmitriptan-2.5, zolmitriptan-5, and sumatriptan-100 showed no net benefits. Results were robust to the sensitivity analyses throughout different scenarios (number of migraine attacks, salary, cost of migraine attack), except when minimal official salary was used in the model. CONCLUSIONS: Compared with existing triptans, eletriptan-40 showed the higher monetary net benefit over the untreated migraine attack alternative, yielding more savings to the Society.
PNL8 COST-EFFECTIVENESS OF BETAHISTINE VS CINNARIZINE FOR VERTIGO
Avksentieva M,Vorobyov P, Leontiev S, Soura M, Morozova S, Yakhno N, Bojko A Moscow medical academy, Moscow, Russia OBJECTIVE: To perform cost-effectiveness analysis of betahistine vs. cinnarizine for vertigo in Russia. METHODS: A total of 240 patients with vertigo were randomized for betahistine 16 mg 3 times a day (group B) or cinnarizine 25 mg 3 times a day (group C) for 3 months. 11 parameters of health status and functional abilities (such as dizziness, nausea, ability to use public transport and others) were measured before the study and by the end of each month using 5-score scale. Absence of severe and moderate functional disabilities (3 scores and more) for all 11 parameters by the end of treatment was the criteria of effectiveness. Direct medical costs were taken into account from the health care system point of view. RESULTS: A total of 215 patients finished the study. There was significant positive dynamics in both groups but in group B positive changes occurred earlier and were more expressed. 86% (95% CI 79.5-92.5%) of patients in B group and 39% (95% CI 29.6-48.4%) in group C had no severe and moderate functional disabilities by the end of study. Median direct cost was 9177.2 rubles ($328 USD) in group B and 6425.6 rubles ($229) in group C. Betahistine was significantly more effective and more costly. Incremental CER was 5854.47 extra
